Published within
|«
«
|
...
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Algeta has announced that Apharadin met its primary endpoint in a bone marker analysis in a phase II hormone-refractory prostate cancer trial, demonstrating its potential in bone metastases. However, this must be translated into survival and/or quality-of-life advantage to guarantee a successful launch. Algeta must also find a suitable marketing partner to bring the product to the market.
Published By Datamonitor
|
27 Feb 2006 |
|
CommentWire
|
The FDA has warned of the risk of injection site reactions to Vivitrol, a once-monthly injection drug for the treatment of alcohol dependence. However, due to the considerable adverse health consequences related to alcohol dependence, along with the limited number of prescription drugs available, Datamonitor does not expect Vivitrol to experience a substantial downturn in sales.
Published By Datamonitor
|
13 Aug 2008 |
|
CommentWire
|
Alkermes' [ALKS] stock price has surged on the back of Lilly's [LLY] endorsement of the inhaled insulin project, as the latter seeks to keep up with close rivals Aventis [AVE] and Pfizer [PFE] and their inhaled insulin, Exubera. Yet reports of regulatory hurdles hindering the approval of Exubera means that Eli Lilly's move should be greeted with a certain amount of caution.
Published By Datamonitor
|
12 Aug 2004 |
|
CommentWire
|
Janssen's substantial slice of the lucrative antipsychotics market is under threat, even though the FDA may eventually approve injectable Risperdal if its makers provide more evidence of its safety. The agency has already approved an extended release formulation of Pfizer's Geodon, and this drug will now enjoy substantial first-to-market advantage.
Published By Datamonitor
|
04 Jul 2002 |
|
CommentWire
|
Botox is the first drug to be approved for the treatment of neurogenic overactive bladder in patients who are intolerant to anticholinergic drugs. The lack of dry mouth and constipation side effects with Botox is a big advantage, yet the need for it to be administered by a specialist will limit uptake. Nevertheless, Allergan's commercial resources will help to drive sales in this niche population.
Published By Datamonitor
|
26 Aug 2011 |
|
CommentWire
|
Allergan, the specialty pharmaceutical company originally spun out from GSK in 1989, has seen its sales growth drop in recent years following a number of late-stage pipeline failures. However, the acquisition of breast implant maker Inamed and the anticipated fortunes of key products have helped to suggest more favorable fortunes for Allergan in 2006.
Published By Datamonitor
|
29 Mar 2006 |
|
CommentWire
|
Top-line Phase III clinical trial data of Botox for the prophylactic treatment of chronic migraine showed a statistically significant decrease in the number of headache days at 24 weeks. Depending on full data results expected in mid-2009, Botox could become the first approved treatment for this debilitating and largely underserved condition.
Published By Datamonitor
|
12 Sep 2008 |
|
CommentWire
|
Following positive results from the pivotal Phase II PROPEL trial, pralatrexate has been filed for FDA approval in second-line and higher peripheral T-cell lymphoma treatment. If pralatrexate is approved, its resulting first-to-market status may facilitate its uptake in this underserved patient population and pave the way for extension into more lucrative indications.
Published By Datamonitor
|
26 Mar 2009 |
|
CommentWire
|
Alpharma has received market exclusivity for the anticonvulsant gabapentin, which is currently protected under patent by Pfizer, using the brand name Neurontin. Alpharma is expected to wait for a court ruling on the validity of Pfizer's production patent before entering the market. That should allow time for Pfizer to launch its follow on product, pregabalin, thus protecting future revenues.
Published By Datamonitor
|
03 Feb 2003 |
|
Expert View
|
Although the prevalence of ALS is not very high, this progressive neurodegenerative disease is not as rare as initially thought. The area is also critically underserved with only one approved drug. Although the patient population for ALS is small, the disease presents companies with a variety of opportunities, from off-label use of marketed products to new drugs for use in a host of indications.
Published By Datamonitor
|
07 Nov 2003 |
|
|«
«
|
...
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.